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Effect of Liraglutide on Cardiovascular Outcomes in Elderly
Patients: A Post Hoc Analysis of a Randomized Controlled
Trial
Background: Comorbidities and complications associ-
ated with type 2 diabetes mellitus (T2DM) increase with age,
making treatment of elderly persons with this condition chal-
lenging. Clinical data on the effect of antihyperglycemic treat-
ment on cardiovascular (CV) events in elderly persons are
limited (1). The U.S. Food and Drug Administration and Euro-
pean Medicines Agency recommend collecting comprehen-
sive data on elderly patients with diabetes, particularly those
aged 75 years or older, to inform appropriate treatment of
this growing population (2, 3).
Glucagon-like peptide-1 agonists are among the newer
classes of antihyperglycemic agents recommended to treat
T2DM because they have high glycemic efficacy and low in-
trinsic risk for hypoglycemia and promote weight loss (4). The
LEADER (Liraglutide Effect and Action in Diabetes: Evaluation
of Cardiovascular Outcome Results) trial showed a 13% re-
duction in major adverse cardiovascular events (MACEs) with
liraglutide versus placebo in patients with T2DM at high risk
for CV events (5). According to eligibility criteria, patients
younger than 60 years had CV disease and older patients had
at least 1 risk factor for CV disease.
Objective: To examine the CV effects of liraglutide ver-
sus placebo in patients aged 75 years or older and 60 to 74
years with risk factors for CV disease and in patients
younger than 60 years with CV disease, focusing on the first
2 age subgroups.
Methods and Findings: The study design, methods, and
statistical analysis have been described previously (5). The pri-
mary outcome was time from randomization to the first MACE,
defined as CV death, a nonfatal myocardial infarction, or a
nonfatal stroke. Safety end points included the frequency of
serious adverse events and medical events of special interest
(5). Time-to-event analysis was adjusted for baseline covari-
ates (including baseline CV status and a wider range of CV
factors, such as smoking) (5).
Of the 9340 patients randomly assigned in the LEADER
trial, 836 were aged 75 years or older, 6183 were aged 60 to
74 years, and 2321 were younger than 60 years. Overall, the
baseline characteristics were matched between the treatment
groups across the age subgroups (Table). Major adverse car-
diovascular events occurred more frequently in patients aged
75 years or older than those aged 60 to 74 years, regardless
of treatment.
Patients aged 75 years or older had a 34% and 29% risk
reduction in the frequency of MACEs and expanded MACE
outcomes, respectively, with liraglutide versus placebo. These
reductions seemed less prominent between the 2 treatment
groups in patients aged 60 to 74 years (P for interaction
across all age groups for MACEs and expanded MACE out-
comes = 0.054 and 0.084, respectively) (Figure). Patients in
the liraglutide group had fewer other CV outcomes than those
in the placebo group, regardless of age subgroup (Figure).
The risk reduction in all-cause death with liraglutide versus
placebo was 35% in patients aged 75 years or older versus 6%
in patients aged 60 to 74 years (P for interaction = 0.088)
(Figure).
Overall, 63.5% and 61.7% of patients aged 75 years or
older reported serious adverse events and nonserious medi-
cal events of special interest, respectively, versus 49.5% and
49.8% of patients aged 60 to 74 years. Across these 2 age
subgroups, the treatment groups did not notably differ. The
most common adverse events were neoplasms (10.3% vs.
14.2% in patients aged 60 to 74 years and 75 years or older,
respectively) and gastrointestinal disorders (diarrhea, nausea,
and vomiting in 1.2%, 2.4%, and 1.1% of patients aged 60 to
74 years and 2.8%, 2.9%, and 1.2% in those aged 75 years or
older, respectively). In the liraglutide group versus the pla-
cebo group, more patients had gastrointestinal disorders
(46.6% vs. 33.0%, respectively) and the incidence of acute
gallstone disease was higher (10.0% vs. 6.3%, respectively),
regardless of age subgroup.
Discussion: This post hoc analysis of the LEADER trial (2)
focused on elderly patients at high risk for CV events and
showed that liraglutide significantly reduced the risk for
MACEs, expanded MACE outcomes, and all-cause death in
this population compared with placebo. Benefits seemed
more pronounced in patients aged 75 years or older than in
those aged 60 to 74 years. Our analysis provides important
information about a population in which clinical trial data are
limited.
Limitations of this analysis include the relatively small sub-
group of patients aged 75 years or older versus the overall
population, short follow-up, and the exploratory nature of
post hoc analyses. These results can help physicians make
clinical decisions on optimal management of T2DM in elderly
patients, a vulnerable population in which treatment options
that evidently benefit important clinical end points are limited.
Table. Baseline Demographic and Clinical Characteristics, by Age at Baseline*
Characteristic Age at Baseline













Male, n (%) 775 (64.7) 761 (67.7) 1968 (64.5) 1967 (62.8) 268 (64.1) 264 (63.2)
Mean age (SD), y 55.3 (2.8) 55.3 (2.8) 65.8 (4.1) 65.8 (4.1) 77.9 (2.9) 78.0 (3.1)
Mean BMI (SD), kg/m2 33.4 (6.8) 33.4 (6.9) 32.4 (6.2) 32.4 (6.1) 30.7 (5.4) 30.5 (4.8)
Mean diabetes duration (SD), y 10.9 (7.0) 10.4 (6.8) 13.0 (7.7) 13.3 (8.1) 17.0 (10.3) 15.8 (9.1)
Mean HbA1c level (SD), % 9.0 (1.7) 8.9 (1.6) 8.7 (1.5) 8.6 (1.4) 8.4 (1.4) 8.3 (1.3)
CV history, n (%) 626 (52.3) 585 (52.0) 1089 (35.7) 1083 (34.6) 150 (35.9) 159 (38.0)
MI 500 (41.8) 473 (42.1) 847 (27.7) 812 (25.9) 117 (28.0) 115 (27.5)
Stroke 173 (14.5) 142 (12.6) 332 (10.9) 361 (11.5) 41 (9.8) 54 (12.9)
Smoking status, n (%)
Current 210 (17.5) 209 (18.6) 343 (11.2) 339 (10.8) 14 (3.3) 15 (3.6)
Never 488 (40.8) 411 (36.6) 1267 (41.5) 1310 (41.9) 195 (46.7) 199 (47.6)
Former 499 (41.7) 504 (44.8) 1443 (47.3) 1481 (47.3) 209 (50.0) 204 (48.8)
Mean blood pressure (SD), mm Hg
Systolic 133.4 (17.3) 132.7 (17.0) 136.8 (17.7) 136.7 (17.7) 136.5 (19.4) 138.3 (18.6)
Diastolic 79.6 (9.8) 78.9 (9.7) 77.0 (10.2) 76.7 (10.2) 72.2 (10.4) 73.7 (10.3)
Mean heart rate (SD), beats/min 74.0 (10.9) 74.2 (10.6) 72.5 (11.4) 72.2 (11.5) 70.1 (11.4) 70.7 (12.2)
Mean eGFR (SD), mL/min/1.73 m2‡ 89.8 (28.3) 90.3 (27.8) 78.8 (26.3) 79.2 (26.3) 62.9 (23.2) 65.0 (22.1)
CKD stage, n (%)
Severe (eGFR <30 mL/min/1.73 m2) 25 (2.1) 23 (2.0) 63 (2.1) 63 (2.0) 29 (6.9) 21 (5.0)
Moderate (eGFR, 30–59 mL/min/1.73 m2) 148 (12.4) 130 (11.6) 672 (22.0) 641 (20.5) 179 (42.8) 164 (39.2)
Mild (eGFR, 60–89 mL/min/1.73 m2) 422 (35.3) 380 (33.8) 1349 (44.2) 1420 (45.4) 161 (38.5) 175 (41.9)
Normal kidney function
(eGFR, ≥90 mL/min/1.73 m2)
602 (50.3) 591 (52.6) 969 (31.7) 1006 (32.1) 49 (11.7) 58 (13.9)
Mean total cholesterol level (SD)
mmol/L 4.5 (1.2) 4.5 (1.4) 4.4 (1.2) 4.4 (1.1) 4.2 (1.1) 4.3 (1.0)
mg/dL§ 173.7 (46.3) 173.7 (54.0) 169.8 (46.3) 169.8 (42.5) 162.1 (42.5) 166.0 (38.6)
Mean LDL cholesterol level (SD)
mmol/L 2.4 (1.0) 2.4 (1.0) 2.3 (0.9) 2.3 (0.9) 2.2 (0.9) 2.3 (0.9)
mg/dL§ 92.6 (38.6) 92.6 (38.6) 88.8 (34.7) 88.8 (34.7) 84.9 (34.7) 88.8 (34.7)
Mean HDL cholesterol level (SD)
mmol/L 1.1 (0.3) 1.1 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 1.3 (0.4)
mg/dL§ 42.5 (11.6) 42.5 (11.6) 46.3 (11.6) 46.3 (11.6) 46.3 (11.6) 50.2 (15.4)
Mean triglyceride level (SD)
mmol/L 2.3 (1.6) 2.4 (2.5) 2.0 (1.4) 2.0 (1.4) 1.8 (1.0) 1.7 (1.0)
mg/dL§ 203.6 (141.6) 212.4 (221.3) 177.0 (123.9) 177.0 (123.9) 159.3 (88.5) 150.5 (88.5)
BMI = body mass index; CKD = chronic kidney disease; CV = cardiovascular; eGFR = estimated glomerular filtration rate; HbA1c = hemoglobin A1c;
HDL = high-density lipoprotein; LDL = low-density lipoprotein; MI = myocardial infarction.
* Percentages may not sum to 100 due to rounding.
† All patients in this age group had a history of CV disease in accordance with the eligibility criteria.
‡ Calculated using the Modification of Diet in Renal Disease equation.
§ Values were calculated and not measured.
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Figure. First occurrence of a MACE and secondary outcomes, by age at baseline.
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AP = angina pectoris; CV = cardiovascular; HF = heart failure; MACE = major adverse cardiovascular event; MI = myocardial infarction.
* For the interaction between treatment and the 3 subgroups by age. A significant value (P < 0.05) indicates that the treatment effect was not
consistent across subgroups. Analyses were adjusted for baseline covariates (including CV status at baseline as defined in the primary analysis [5]
and a wider range of CV factors, such as smoking). No adjustment was done for multiple testing. Secondary CV end points included an expanded
composite MACE outcome that comprised a MACE (as defined by the primary end point) or coronary revascularization, hospitalization for unstable
AP or HF, each component of the composite CV outcomes, and all-cause and non-CV death.
† 1197 patients were in the liraglutide group, and 1124 were in the placebo group.
‡ 3053 patients were in the liraglutide group, and 3130 were in the placebo group.
§ 418 patients were in the liraglutide group, and 418 were in the placebo group.
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José Francisco Kerr Saraiva, MD, PhD
Pontifı́cia Universidade Cató lica de Campinas
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